Thurston Springer Miller Herd & Titak’s Novartis NVS Stock Holding History
Bought
Maintained
Sold
Other funds holding NVS
Thurston Springer Miller Herd & Titak's NVS Position: Q2 2026 in Review
Thurston Springer Miller Herd & Titak increased its Novartis (NVS) stake by 10% in Q2 2026, buying an estimated $2.55K and bringing the position to 180 shares worth $28.2K. The position accounts for 0.01% of the portfolio, ranked #596.
Thurston Springer Miller Herd & Titak first reported a position in NVS in Q2 2024 and has held it in 9 quarters since. The position peaked at $220K in Q2 2025. 1,621 funds tracked by Wall St. Rank hold NVS as of Q2 2026.
- Thurston Springer Miller Herd & Titak held 180 shares of Novartis worth $28.2K as of Q2 2026.
- Thurston Springer Miller Herd & Titak bought 17 Novartis shares in Q2 2026, an estimated $2.55K.
- Novartis made up 0.01% of Thurston Springer Miller Herd & Titak's portfolio in Q2 2026, its #596 holding.
- Thurston Springer Miller Herd & Titak first reported a position in Novartis in Q2 2024 and has held it in 9 quarters since.
- Thurston Springer Miller Herd & Titak's Novartis position peaked at $220K in Q2 2025.
- 1,621 funds tracked by Wall St. Rank held Novartis as of Q2 2026.
Based on Thurston Springer Miller Herd & Titak's 13F filing for Q2 2026, filed 8 Jul 2026.